← Back to Search

Antibody-drug conjugate

TR1801-ADC for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Open Innovation Partners, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3.5 years

Awards & highlights

Study Summary

This trial is to see if a new cancer medication is safe and effective.

Eligible Conditions

Unspecified Adult Solid Tumor Protocol Specific

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met

Establish maximum tolerated dose

Secondary outcome measures

Evaluate clinical activity of TR1801-ADC

Evaluate pharmacokinetics of TR1801-ADC

Immunogenicity

Trial Design

1Treatment groups

Experimental Treatment

Group I: TR1801-ADCExperimental Treatment1 Intervention

Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Open Innovation Partners, Inc.Lead Sponsor

Tanabe Research Laboratories USA IncLead Sponsor

Open Innovation PartnersUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locales are supervising this clinical experiment?

"USC Norris Comprehensive Cancer Center in Los Angeles, Hoag Memorial Hospital Presbyterian in Newport Beach, and John Hopkins - Sidney Kimmel Comprehensive Cancer Center are among the 5 locations that are hosting this medical trial."

Answered by AI

Are there any remaining opportunities to participate in this research endeavor?

"As evidenced on clinicaltrials.gov, the posting for this trial has since expired; it was initially published in August 14th 2019 before being last revised October 30th 2022. Nonetheless, there are still 2,408 other studies actively recruiting candidates at present."

Answered by AI

What assessments have been done to gauge the security of TR1801-ADC for patients?

"Currently, there is limited clinical data to suggest the safety and efficacy of TR1801-ADC. Therefore, our team gave it a rating of 1 on a scale from 1-3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

TR1801-ADC in Patients With Tumors That Express c-Met

2019. "TR1801-ADC in Patients With Tumors That Express c-Met". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859752.